Literature DB >> 8225748

HTLV-I/II infections in Spain. The HTLV-I/II Spanish Study Group.

V Soriano1, E Calderón, B Esparza, G Cilla, A Aguilera, M Gutiérrez, J Tor, E Pujol, F Merino, E Pérez-Trallero.   

Abstract

Antibodies to HTLV-I/II were investigated in sera from 7521 individuals living in Spain. They were classified in four major groups: a) subjects at high risk of retroviral infections e.g. parenteral drug addicts, homosexuals, prostitutes, and multiple-transfused individuals; b) patients suffering illness associated with HTLV-I in endemic regions; c) immigrants from endemic areas; and d) blood donors. Sera were collected from 1984 to December 1991. Repeatedly reactive ELISA was found in 211 samples (2.8%), but Western blot only confirmed the presence of HTLV-I/II antibodies in 23 samples (0.30%), corresponding to eight (0.25%) out of 3207 drug abusers, six (0.72%) out of 894 immigrants (five Africans and one South American), three (0.41%) out of 727 patients with HTLV-related diseases (one woman with HTLV-I associated myelopathy had received blood transfusions in an endemic area), four (0.54%) out of 793 prostitutes, one multiple-transfused native woman, and one (0.16%) out of 603 native seamen. The Western blot antibody pattern confirmed HTLV-II infection instead of HTLV-I in nine (39%) subjects. The remaining 14 (61%) HTLV-reactive samples were interpreted as HTLV-I seropositive, most of which were from immigrants. None of 857 blood donors analysed was reactive for HTLV antibody. These results suggest that both HTLV-I and HTLV-II are present in Spain, although at a low rate and mostly restricted to individuals coming from endemic areas, drug addicts, and prostitutes. Furthermore, diseases related to HTLV-I (particularly lymphoproliferative disorders, and subacute myelopathies) seem to be rarely associated with these viruses in Spain, a non-endemic area.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8225748     DOI: 10.1093/ije/22.4.716

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  6 in total

Review 1.  The origin and evolution of human T-cell lymphotropic virus types I and II.

Authors:  Y Suzuki; T Gojobori
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

2.  Prevalence of infection by human T-cell leukemia virus types I and II in southern Spain.

Authors:  E J Calderón; C Rey; F J Medrano; J Sánchez-Román; V Soriano; Y Torres; M Ruiz; E Lissen; M Leal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267

3.  Epidemiology of human T-lymphotropic virus type II (HTLV-II) infection in Spain. HTLV Spanish Study Group.

Authors:  V Soriano; A Vallejo; M Gutiérrez; C Tuset; G Cilla; R Martínez-Zapico; F Dronda; E Caballero; E Calderón; A Aguilera; A M Martín; J Llibre; J del Romero; R Ortiz de Lejarazu; F Ulloa; J Eirós; J González-Lahoz
Journal:  Eur J Epidemiol       Date:  1996-12       Impact factor: 8.082

4.  Phylogenetic relationship and geographic distribution of multiple human T-cell lymphotropic virus type II subtypes.

Authors:  W M Switzer; D Pieniazek; P Swanson; H H Samdal; V Soriano; R F Khabbaz; J E Kaplan; R B Lal; W Heneine
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

5.  Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group.

Authors:  D R Henrard; V Soriano; E Robertson; M Gutierrez; J Stephens; F Dronda; F Miles; E Pujol; M Buytendorp; A Castro
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

6.  Epidemiology of HIV-2 infection in Spain. The HIV-2 Spanish Study Group.

Authors:  V Soriano; M Gutiérrez; E Caballero; G Cilla; J L Fernández; A Aguilera; C Tuset; F Dronda; A M Martín; E Carballo; I López; J González-Lahoz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.